Biogen (BIIB) Revenue & Quarterly History
Explore Biogen Inc. (BIIB) revenue from 2023 through the latest reported quarter, with SEC-sourced comparisons and filing-constrained analysis.
Key takeaway
Quarter ended Mar 31, 2026 · FY2026 Q1
Revenue increased in the current quarter compared to both the immediately preceding quarter and the same quarter one year earlier. The sequential improvement reversed a decline seen in the prior quarter.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.5B
Revenue reported for this quarter.
Quarter-over-quarter
+8.7%
Change from the immediately preceding quarter.
Year-over-year
+1.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$9.9B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2025 | $2.6B | +7.3% |
| Sep 30, 2025 | $2.5B | +2.8% |
| Dec 31, 2025 | $2.3B | -7.1% |
| Mar 31, 2026 | $2.5B | +1.9% |
Revenue performance
The reported revenue rose from the prior quarter, marking a positive sequential change after a decrease in the previous period.
Quarterly comparison
Compared with the immediately preceding quarter, revenue increased. Compared with the same quarter one year earlier, revenue also increased.
What to watch
The proposed acquisition of Apellis Pharmaceuticals, if completed, could affect future revenue trends.